| Literature DB >> 35909608 |
Kin P Tao1,2,3,4, Marc K C Chong5, Kathy Y Y Chan1, Jason C S Pun1,2,3,4, Joseph G S Tsun1,2,3,4, Samuel M W Chow6, Calvin S H Ng7, Maggie H T Wang5, Paul K S Chan8, Albert M Li1,2,3,4, Renee W Y Chan1,2,3,4.
Abstract
Background: Influenza virus (IV) and the rhinovirus (RV) are the two most common circulating respiratory viruses circulating. Natural viral interference has been suggested between them. The effect of such at the population level has been described in temperate region, while its effect at the individual and cellular levels warrants further validation. In this study, we described the respiratory virus epidemiology and the co-infection landscape in the hospitalized population and investigated the distinct molecular pathways involved in the inhibition of virus replication.Entities:
Keywords: Co-infection; Influenza; Rhinovirus; Viral epidemiology; Viral interference
Year: 2022 PMID: 35909608 PMCID: PMC9325905 DOI: 10.1016/j.crmicr.2022.100147
Source DB: PubMed Journal: Curr Res Microb Sci ISSN: 2666-5174
Fig. 1Temporal dynamics of respiratory virus prevalence in the inpatient cohort from September 2015 to December 2019. Monthly prevalence of individual virus infections (left y-axis) with the respective number of tested samples showed in gray bars (right y-axis) throughout the study period. EV/RV = enterovirus/rhinovirus; IVs = influenza viruses; PIVs = parainfluenza viruses; RSV = respiratory syncytial viruses; ADV = adenovirus. There are typically two influenza seasons in Hong Kong, winter peak from January to April and summer peak from July to August. The number indicates the ten influenza seasons within the study period.
Fig. 2Adjusted relative risks (ARRs) with 95% confidence interval on EV/RV against IV prevalence. The estimated ARRs without controlling meteorological effects, with ambient temperature plus relative humidity controlled, and with actual vapor pressure adjusted are expressed as blue, red, and green colors (from left to right), respectively. Median IV prevalence was used as the reference value for comparison. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3(A) Demographics of the patients included in the inpatient study from September 2015 to December 2019. Virological readouts were obtained from all 112,926 NPA samples for the detection of virus infection by multiplex PCR. Subtyping of H1 and H3 were performed after positive IAV detection. Due to the variation of the dominant IV species and subtypes each year, IAV-H1, IAV-H3, IBV, and ICV were combined as IVs for regression analyses. (B) Prevalence of individual virus infections of different age groups is represented by the color lines (left y-axis). The gray bar represents the number of samples tested in each group (right y-axis). (C) The age distribution of virus infections from test-positive 39,190 NPA samples presents individual data as gray dots. The black line shows the median age, and the red lines show the interquartile range. (D) Logistic regression between the prevalence of EV/RV with other viruses with 95% CI marked in dotted lines. Significant negative correlation (−1·60 ± 0·31, p < 0·0001*** with R2 = 0·3123) was identified only between EV/RV and IVs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Correlation of viral prevalence in hospitalized subjects. Bivariate Spearman's cross-correlation coefficients (rs) between respiratory viruses using the monthly prevalence are shown. Asterisks indicate significance at p < 0·05*, p < 0·01** and p < 0·001***. IVs in the last column indicates the sum of IAV, IBV and ICV, the cross-correlation within the IVs and IAV, IBV and ICV are therefore excluded from the analysis. Red and blue values indicate a negative and positive correlation, respectively.
| IAV | IBV | ICV | PIV1 | PIV2 | PIV3 | PIV4 | RSV | ADV | IVs | |
|---|---|---|---|---|---|---|---|---|---|---|
| −0·421** | 0·096 | −0·223 | 0·117 | 0·114 | 0·240 | 0·147 | 0·052 | 0·138 | −0·477*** | |
| −0·217* | −0·025 | 0·126 | −0·350** | −0·184 | 0·042 | 0·078 | −0·120 | – | ||
| 0·081 | −0·186 | −0·289* | 0·224 | −0·232 | −0·022 | −0·100 | – | |||
| −0·147 | 0·277* | 0·138 | 0·025 | −0·426** | −0·125 | – | ||||
| 0·038 | 0·275 | 0·415* | −0·172** | −0·051 | 0·047 | |||||
| 0·098 | −0·053 | −0·178 | −0·090 | −0·428** | ||||||
| 0·084 | −0·396* | −0·011 | −0·061 | |||||||
| −0·047 | 0·059 | −0·109** | ||||||||
| −0·032 | −0·044 | |||||||||
| −0·199 |
Fig. 4Co-infection statistics. (A) Rate of co-detecting more than one respiratory virus in different respiratory virus infection. The number of NPA samples detected with more than one pathogen detected was divided by the total number of the sample test-positive with the agent listed in each row. (B) Breakdown of co-infection cases according to age group. (C) The odd ratio of EV/RV and IVs co-infection with other respiratory pathogens using Fisher's exact test with null hypothesis assuming the likelihood of individual infection events were not interrelated. (D) Logistic regression analysis of EV/RV and IV infection after adjustment to gender and age group.
Fig. 5RVs suppress subsequent IVs infection in vitro. (A) Experimental plan of the model. Fully differentiated ALI cultures were first infected (or sham-exposed) with RV-A16 for 2 days, followed by secondary infection of IVs. Supernatant and cell lysates were collected at 2, 24 and 48 h post infection (hpi) for determination of viral load and gene expression. (B) Suppression of IAV titers with prior RV-A16 infection in HBEC (n = 7) and HNEC (n = 4). Y-axis represents the difference in titer in RV exposed to the sham-exposed cells. (C) Suppression of IBV and oseltamivir-resistance stain of IAV (R-IAV) in HBEC with prior RV-A16 exposure. Error bars showing the SEM of means and asterisks indicating significance of p < 0·05*, and p < 0·01** compared with sham treatment as examined by two way ANOVA followed by Bonferroni's multiple comparisons test.
Fig. 6RNA-seq analysis revealed signature gene sets enriched in HBECs upon RV infection. (A) Venn analysis showing the number of DEGs that are specifically or commonly enriched in RV or IAV infected cells when compared to respective sham controls. (B) Volcano plot displaying transcripts which were differentially expressed upon RV but not by IAV infection. Only transcripts with fold change >2 and FDR <0.05 were displayed. GSEA analysis showing top pathways that were (C) positively or (D) negatively enriched in RV-infected cells in contrast to IAV infected counterparts. Gene expression in selected Reactome pathways that were uniquely enriched upon RV infection. (E) Positive enrichment in ISG15 antiviral mechanism pathway. (F) Negative enrichment in eukaryotic translation initiation pathway.